We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current PSTX market cap is 277.89M. The company's latest EPS is USD -1.2792 and P/E is -2.24.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 116.31M | 10.05M | 10.34M | 20.01M | 9.35M |
| Operating Income | 71.78M | -33.22M | -39.52M | -27.86M | -36.22M |
| Net Income | 70.41M | -33.32M | -38.85M | -27.46M | -31.78M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 31.24M | 130.49M | 64.7M |
| Operating Income | -85.53M | -126.55M | -141.41M | -59.95M | -129.5M |
| Net Income | -86.53M | -129.78M | -124.97M | -64M | -123.43M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 380.48M | 351.84M | 313.62M | 281.22M | 302.25M |
| Total Liabilities | 164.17M | 164.24M | 156.06M | 145.91M | 178.59M |
| Total Equity | 216.31M | 187.6M | 157.57M | 135.3M | 123.66M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 147M | 371.48M | 269.31M | 351.84M | 273.89M |
| Total Liabilities | 74.33M | 109.52M | 113.1M | 164.24M | 170.18M |
| Total Equity | -149.51M | 261.97M | 156.21M | 187.6M | 103.7M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -29.18M | -26.77M | -38.01M | -71.31M | -63.42M |
| Investing | -117.44M | -203.33M | -4.42M | 38.66M | -8.58M |
| Financing | 105.1M | 105.16M | 1.19M | 1.19M | 16.13M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -64.39M | -113.33M | -102.54M | -26.77M | -92.17M |
| Investing | -42.59M | -204.43M | 222.38M | -203.33M | 39.13M |
| Financing | 164.37M | 313.94M | 2.52M | 105.16M | 16.13M |
| Market Cap | 277.89M |
| Price to Earnings Ratio | -2.24 |
| Price to Sales Ratio | 4.28 |
| Price to Cash Ratio | 6.23 |
| Price to Book Ratio | 2.67 |
| Dividend Yield | - |
| Shares Outstanding | 96.49M |
| Average Volume (1 week) | 1.11M |
| Average Volume (1 Month) | 673k |
| 52 Week Change | 8.27% |
| 52 Week High | 4.27 |
| 52 Week Low | 1.54 |
| Spread (Intraday) | 1.04 (26.74%) |
| Company Name | Poseida Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.poseida.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
